Alnylam Pharmaceuticals Inc. (ALNY) Given a $106.00 Price Target at Piper Jaffray Cos.
Piper Jaffray Cos. set a $106.00 price objective on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a report released on Thursday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
A number of other analysts also recently issued reports on ALNY. Credit Suisse Group AG reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Cowen and Company reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, June 27th. Finally, FBR & Co restated a buy rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $86.00.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 7.98% during trading on Thursday, hitting $33.32. 4,365,590 shares of the company’s stock were exchanged. The company has a 50-day moving average of $71.80 and a 200-day moving average of $66.24. The company’s market cap is $2.86 billion. Alnylam Pharmaceuticals has a 12-month low of $33.21 and a 12-month high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.09 million. During the same period in the prior year, the firm posted ($0.85) earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Geode Capital Management LLC raised its position in Alnylam Pharmaceuticals by 7.1% in the first quarter. Geode Capital Management LLC now owns 480,181 shares of the biopharmaceutical company’s stock valued at $30,123,000 after buying an additional 31,627 shares during the last quarter. Altrinsic Global Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $4,250,000. AXA raised its position in Alnylam Pharmaceuticals by 50.5% in the first quarter. AXA now owns 98,689 shares of the biopharmaceutical company’s stock valued at $6,195,000 after buying an additional 33,116 shares during the last quarter. State Street Corp raised its position in Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock valued at $121,553,000 after buying an additional 262,783 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Alnylam Pharmaceuticals by 348.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,321 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 10,348 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.